Momenta, Mylan to jointly develop six biosimilars

January 8, 2016 2:10 PM

40 0

Momenta, Mylan to jointly develop six biosimilars

Companies will equally share R&D costs and profits

Mylan NV and Momenta Pharmaceuticals Inc. said Friday they would jointly develop and commercialize six biosimilars.

Also read: FDA approves Gilead's drug for chronic hep C patients

Read more

To category page

Loading...